Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation

Haematologica

Volumn 93, Issue 4, 2008, Pages 605-609

  Canalli, Andreia A ^a   Franco Penteado, Carla F ^a   Saad, Sara T O ^a   Conran, Nicola ^a   Costa, Fernando Ferreira ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Adhesion; Leukocyte; Nitric oxide; Sickle cell disease; Vaso occlusion

Indexed keywords

3,3 BIS(2 AMINOETHYL) 1 HYDROXY 2 OXOTRIAZENE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; CYCLIC GMP; FIBRONECTIN; GUANYLATE CYCLASE INHIBITOR; HYDROXYUREA; INTERCELLULAR ADHESION MOLECULE 1; NITRIC OXIDE; NITROPRUSSIDE SODIUM; OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; IN VITRO STUDY; LEUKOCYTE ADHERENCE; MAJOR CLINICAL STUDY; NEUTROPHIL; SICKLE CELL ANEMIA; VASCULAR ENDOTHELIUM;

ADULT; ALPHA-THALASSEMIA; ANEMIA, SICKLE CELL; ANTIGENS, CD11A; ANTIGENS, CD11B; CELL ADHESION; CYCLIC GMP; ENDOTHELIAL CELLS; FEMALE; FIBRONECTINS; HUMANS; HYDRAZINES; HYDROXYUREA; INTEGRIN ALPHA4; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; NEUTROPHILS; NITRIC OXIDE; NITRIC OXIDE DONORS; NITROPRUSSIDE; OXADIAZOLES; PYRAZOLES; PYRIDINES; QUINOXALINES; SICKLE CELL TRAIT;

EID: 42149134238     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12119     Document Type: Article

References (26)

1. Okpala I. The intriguing contribution of white blood cells to sickle cell disease - a red cell disorder. Blood Rev 2004;18:65-73.
2. Chiang EY, Frenette PS. Sickle cell vaso-occlusion. Hematol- Oncol Clin North Am 2005;19:771-84.
3. Fadlon E, Vordermeier S, Pearson TC, Mire-Sluis AR, Dumonde DC, Phillips J, et al. Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64. Blood 1998;91:266-74.
4. Petri B, Bixel MG. Molecular events during leukocyte diapedesis. Febs J 2006;273:4399-407.
5. Lum AF, Wun T, Staunton D, Simon SI. Inflammatory potential of neutrophils detected in sickle cell disease. Am J Hematol 2004;76:126-33.
6. Assis A, Conran N, Canalli AA, Lorand-Metze I, Saad ST, Costa FF. Effect of cytokines and chemokines on sickle neutrophil adhesion to fibronectin. Acta Haematologica 2005;113:130-6.
7. Mack AK, Kato GJ. Sickle cell disease and nitric oxide: a paradigm shift¿ Int J Biochem Cell Biol 2006;38:1237-43.
8. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995;96:60-8.
9. Conran N, Gambero A, Ferreira HH, Antunes E, de Nucci G. Nitric oxide has a role in regulating VLA-4-integrin expression on the human neutrophil cell surface. Biochem Pharmacol 2003;66:43-50.
10. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995;332:1317-22.
11. Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol 1992;19:1-10.
12. Ikuta T, Ausenda S, Cappellini MD. Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway. Proc Natl Acad Sci USA 2001;98:1847-52.
13. Cokic VP, Smith RD, Beleslin-Cokic BB, Njoroge JM, Miller JL, Gladwin MT, et al. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest 2003;111:231-9.
14. Cokic VP, Beleslin-Cokic BB, Tomic M, Stojilkovic SS, Noguchi CT, Schechter AN. Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells. Blood 2006;108:184-91.
15. Canalli AA, Franco-Penteado CF, Traina F, Saad ST, Costa FF, Conran N. Role for cAMP-protein kinase A signalling in augmented neutrophil adhesion and chemotaxis in sickle cell disease. Eur J Haematol 2007;79:330-7.
16. Conran N, Almeida CB, Lanaro C, Ferreira RP, Traina F, Saad ST, et al. Inhibition of caspase-dependent spontaneous apoptosis via a cAMP-protein kinase A dependent pathway in neutrophils from sickle cell disease patients. Br J Haematol 2007;139:148-58.
17. Shimaoka M, Takagi J, Springer TA. Conformational regulation of integrin structure and function. Annu Rev Biophys Biomol Struct 2002;31:485-516.
18. Hogg N, Leitinger B. Shape and shift changes related to the function of leukocyte integrins LFA-1 and Mac-1. J Leukoc Biol 2001;69:893-8.
19. Burns JA, Issekutz TB, Yagita H, Issekutz AC. The α 4 β 1 (very late antigen (VLA)-4, CD49d/CD29) and α 5 β 1 (VLA-5, CD49e/CD29) integrins mediate β 2 (CD11/CD18) integrin-independent neutrophil recruitment to endotoxin-induced lung inflammation. J Immunol 2001;166:4644-9.
20. Gries A, Bode C, Peter K, Herr A, Bohrer H, Motsch J, et al. Inhaled nitric oxide inhibits human platelet aggregation, P-selectin expression, and fibrinogen binding in vitro and in vivo. Circulation 1998;97:1481-7.
21. Nahavandi M, Tavakkoli F, Wyche MQ, Perlin E, Winter WP, Castro O. Nitric oxide and cyclic GMP levels in sickle cell patients receiving hydroxyurea. Br J Haematol 2002;119:855-7.
22. Conran N, Oresco-Santos C, Acosta HC, Fattori A, Saad ST, Costa FF. Increased soluble guanylate cyclase activity in the red blood cells of sickle cell patients. Br J Haematol 2004;124:547-54.
23. Boerrigter G, Burnett JC, Jr. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease. Cardiovasc Drug Rev 2007;25:30-45.
24. Freitas CF, Morganti RP, Annichino-Bizzacchi JM, De Nucci G, Antunes E. Effect of BAY 41-2272 in the pulmonary hypertension induced by heparin-protamine complex in anaesthetized dogs. Clin Exp Pharmacol Physiol 2007;34:10-4.
25. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006;5:755-68.
26. Machado RF, Martyr S, Kato GJ, Barst RJ, Anthi A, Robinson MR, et al. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol 2005;130:445-53.